Piramal Pharma Acquires Additional 40.67% Stake in Yapan Bio for ₹76 Crore
Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, strengthening its capabilities in biologics, vaccines, and large-molecule drug development and manufacturing.
The company announced the completion of the transaction on August 18, 2026, following its earlier disclosure dated August 10 regarding the exercise of its call option to acquire additional shares in Yapan Bio.
Piramal Pharma Increases Yapan Bio Stake to 74%
Piramal Pharma has acquired 1,46,400 equity shares of Yapan Bio, having a face value of ₹10 each, from existing shareholders.
The aggregate cash consideration for the transaction was approximately ₹76 crore.
Following the acquisition, Piramal Pharma’s ownership in Yapan Bio has increased from 33.33% to 74%.
As a result, Yapan Bio has ceased to be an associate company and has become a subsidiary of Piramal Pharma.
The transaction further strengthens Piramal Pharma’s presence in the contract development and manufacturing space, particularly in complex biologic therapies.
Yapan Bio: Focus on Vaccines and Biologics
Yapan Bio Private Limited was incorporated on October 11, 2019, under the Companies Act, 2013.
The company operates as a Contract Development and Manufacturing Organization (CDMO) and specializes in:
- Process development
- Process characterization
- Phase I GMP manufacturing
- Phase II GMP manufacturing
- Vaccines
- Biologics
Yapan’s capabilities are particularly relevant to the growing demand for development and manufacturing services for complex biological therapies.
Yapan Bio Revenue Performance
Yapan Bio has reported revenue from operations across the last three financial years as follows:
- FY2024: ₹26.91 crore
- FY2025: ₹54.40 crore
- FY2026: ₹26.34 crore
The company recorded a significant increase in revenue during FY2025 before revenue declined in FY2026.
With Piramal Pharma now holding a controlling 74% stake, the integration of Yapan’s capabilities could provide opportunities to leverage Piramal Pharma’s broader platform and customer relationships.
Piramal Pharma Strengthens Large-Molecule Capabilities
The acquisition is strategically important because it expands Piramal Pharma’s capabilities in large-molecule and biologics services.
According to the company, Yapan’s advanced large-molecule capabilities will be embedded into Piramal Pharma’s integrated service offering.
This is expected to help the company develop and scale complex biologic therapies more efficiently.
The move also complements Piramal Pharma’s existing CDMO operations and its broader strategy of expanding its capabilities across the pharmaceutical value chain.
Why the Yapan Bio Acquisition Matters
The pharmaceutical industry is witnessing increasing demand for specialized CDMO services as drug developers look to outsource complex development and manufacturing activities.
Biologics and other large-molecule therapies generally require specialized manufacturing infrastructure, process development expertise, and stringent quality systems.
By increasing its stake in Yapan Bio to 74%, Piramal Pharma can now exercise greater control over the company’s operations and integrate its capabilities more closely with the broader business.
The transaction could therefore help Piramal Pharma strengthen its offering in complex biologics, vaccines and early-stage clinical manufacturing.
What This Means for Piramal Pharma
The acquisition represents another step in Piramal Pharma’s efforts to build an integrated pharmaceutical services platform.
With Yapan Bio becoming a subsidiary, Piramal Pharma gains greater ownership of its capabilities in large-molecule development and GMP manufacturing.
The company can potentially use these capabilities to support customers from development through clinical manufacturing, creating a more comprehensive CDMO offering.
Key Points
- Piramal Pharma acquired an additional 40.67% stake in Yapan Bio.
- Transaction value was approximately ₹76 crore.
- Piramal Pharma’s stake increased from 33.33% to 74%.
- Yapan Bio is now a subsidiary of Piramal Pharma.
- Yapan operates as a CDMO focused on vaccines and biologics.
- Its capabilities include process development, characterization, and Phase I/II GMP manufacturing.
- Yapan reported FY2026 revenue of ₹26.34 crore.
- The acquisition strengthens Piramal Pharma’s large-molecule and biologics capabilities.
- Piramal Pharma expects to integrate Yapan’s capabilities into its broader service offering.
The acquisition of an additional stake in Yapan Bio gives Piramal Pharma greater control over a business operating in the specialized biologics and large-molecule CDMO segment.
As demand for complex biologic therapies continues to develop, the integration of Yapan’s capabilities could help Piramal Pharma expand its end-to-end development and manufacturing offering.
The key areas to watch going forward will be the integration of Yapan into Piramal Pharma’s operations, revenue growth at Yapan, capacity utilization and the company’s ability to convert its expanded biologics capabilities into new customer opportunities.
Disclaimer: This article is based on the disclosure made by Piramal Pharma Limited on August 18, 2026. It is intended for informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security.